Academic Medical Center/University of Amsterdam, The Netherlands.
Radiotherapy Group, Arnhem, The Netherlands.
Radiother Oncol. 2017 Mar;122(3):340-346. doi: 10.1016/j.radonc.2016.12.022. Epub 2016 Dec 31.
The standard treatment for muscle-invasive bladder cancer (MIBC) is a radical cystectomy with pelvic lymph node dissection with or without neoadjuvant chemotherapy. In selected cases a bladder sparing approach is possible, for example a limited surgical excision combined with external beam radiotherapy and brachytherapy. To perform brachytherapy flexible catheters have to be implanted in the bladder wall. The implantation is done either by the open retropubic approach or the endoscopic surgical approach. The largest experience for brachytherapy is with low-dose rate and pulsed-dose rate, although some short-term experience with high-dose rate is also reported. The main advantage for this technique is the conservation of bladder function, with comparable local control rates as for cystectomy series in selected cases. The GEC-ESTRO/ACROP (Groupe Européen de Curiethérapie-European Society for Radiotherapy and Oncology / Advisory Committee on Radiation Oncology Practice) recommendations to perform bladder implantations and brachytherapy as a treatment option for MIBC are described.
肌层浸润性膀胱癌(MIBC)的标准治疗方法是根治性膀胱切除术加盆腔淋巴结清扫术,可辅以新辅助化疗。在某些特定情况下,可行保留膀胱的治疗方法,例如有限的手术切除联合外照射放疗和近距离放疗。为了实施近距离放疗,必须将柔性导管植入膀胱壁。植入可以通过经耻骨后开放入路或内镜手术入路来完成。虽然也有一些关于高剂量率的短期经验报告,但低剂量率和脉冲剂量率的近距离放疗的经验最丰富。该技术的主要优势在于保留膀胱功能,在某些特定情况下,其局部控制率与膀胱切除术系列相当。欧洲放射治疗与肿瘤学会(ESTRO)/辐射肿瘤学实践咨询委员会(ACROP)推荐将膀胱植入和近距离放疗作为 MIBC 的治疗选择,现对其操作指南进行描述。